About Applied Therapeutics Inc
Ticker
info
APLT
Trading on
info
NASDAQ
ISIN
info
US03828A1016
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Les D. Funtleyder
Headquarters
info
545 Fifth Avenue, New York, NY, United States, 10017
Employees
info
36
Website
info
appliedtherapeutics.com
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Metrics
BasicAdvanced
Market cap
info
$58.6M
P/E ratio
info
-
EPS
info
-$0.24
Dividend Yield
info
0.00%
Beta
info
1.87
Forward P/E ratio
info
0
EBIDTA
info
$-109M
Ex dividend date
info
-
Price & volume
Market cap
info
$58.6M
Average daily volume
info
2.7M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
221.13
Price to book
info
1.6
Earnings
EPS
info
-$0.24
EPS estimate (current quarter)
info
-$0.19
EPS estimate (next quarter)
info
-$0.18
EBITDA
info
$-109M
Revenues (TTM)
info
$0.3M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.87
52-week High
info
$10.62
52-week Low
info
$0.30
50-day moving average
info
$0.39
200-day moving average
info
$2.56
Short ratio
info
8.79
Short %
info
15.17%
Management effectiveness
ROE (TTM)
info
-83.71%
ROA (TTM)
info
-65.30%
Profit margin
info
0.00%
Gross profit margin
info
$-44.1M
Operating margin
info
-41,030.57%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-98.20%
Share stats
Outstanding Shares
info
142M
Float
info
118M
Insiders %
info
5.49%
Institutions %
info
83.05%
Analyst Insights & forecasts
info

50% Buy

50% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$5.63
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.02
-$0.16
112.50%
Q2 • 24Beat
-$0.48
-$0.16
-200.00%
Q3 • 24Missed
$0.33
-$0.17
297.96%
Q4 • 24Beat
$0.33
-$0.19
277.35%
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$44M
∞%
Q4 • 24
$-0M
$-21.8M
2,182,500.00%
Q1 • 25
-∞%
-149.59%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$86.7M
$29.7M
34.24%
Q4 • 24
$56.9M
$20.2M
35.57%
Q1 • 25
-34.36%
-31.82%
3.86%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-19.5M
$0M
$0M
$-19.5M
Q4 • 24
$-28.6M
$0M
$0M
$-28.6M
Q1 • 25
47.09%
-
NaN%
47.09%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Applied Therapeutics Inc share?
Collapse

Applied Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Applied Therapeutics Inc have?
Collapse

Applied Therapeutics Inc currently has 142M shares.

Does Applied Therapeutics Inc pay dividends?
Collapse

No, Applied Therapeutics Inc doesn't pay dividends.

What is Applied Therapeutics Inc 52 week high?
Collapse

Applied Therapeutics Inc 52 week high is $10.62.

What is Applied Therapeutics Inc 52 week low?
Collapse

Applied Therapeutics Inc 52 week low is $0.30.

What is the 200-day moving average of Applied Therapeutics Inc?
Collapse

Applied Therapeutics Inc 200-day moving average is $2.56.

Who is Applied Therapeutics Inc CEO?
Collapse

The CEO of Applied Therapeutics Inc is Les D. Funtleyder.

How many employees Applied Therapeutics Inc has?
Collapse

Applied Therapeutics Inc has 36 employees.

What is the market cap of Applied Therapeutics Inc?
Collapse

The market cap of Applied Therapeutics Inc is $58.6M.

What is the P/E of Applied Therapeutics Inc?
Collapse

The current P/E of Applied Therapeutics Inc is null.

What is the EPS of Applied Therapeutics Inc?
Collapse

The EPS of Applied Therapeutics Inc is -$0.24.

What is the PEG Ratio of Applied Therapeutics Inc?
Collapse

The PEG Ratio of Applied Therapeutics Inc is null.

What do analysts say about Applied Therapeutics Inc?
Collapse

According to the analysts Applied Therapeutics Inc is considered a buy.